Horizon Therapeutics Public Company Stock News

During the last session, Horizon Therapeutics Public Limited Company (NASDAQ:HZNP)s traded shares were 0.78 million, with the beta value of the company hitting 0.99. At the end of the trading day, the stocks price was $104.50, reflecting an intraday loss of -0.35% or -$0.37. The 52-week high for the HZNP share is $120.54, that puts Horizon Therapeutics Public Limited Company (NASDAQ: HZNP) Rose 14.01% In Six Months, Heres What We Should Expect Now Read More »

-- Post hoc analysis of UPLIZNA Phase 2/3 trial shows all seven patients who had attacks while receiving rituximab were attack-free after switching to UPLIZNA -- Horizon Therapeutics plc (Nasdaq:

Parametric Portfolio Associates LLC lessened its stake in Horizon Therapeutics Public Limited (NASDAQ:HZNP) by 2.8% in the 2nd quarter, according to its most recent filing with the SEC. The fund owned 410,382 shares of the biopharmaceutical companys stock after selling 11,717 shares during the period. Parametric Portfolio Associates LLC owned about 0.18% of Horizon Therapeutics []

The HORIZON THERAPEUTICS USA, INC. POLITICAL ACTION COMMITTEE (HORIZON THERAPEUTICS PAC) successfully filed their F3XA OCTOBER MONTHLY with the coverage period of 09/01/2021 to 09/30/2021 and a confirmation ID of FEC-1549551 *********CommitteeId: C00624148 | FilingId: 1549551 | FormType: F3XA | CoverageFrom: 09/01/2021 | CoverageThrough: 09/30/2021 | ReportType: OCTOBER MONTHLY*********

Horizon Therapeutics Public (NASDAQ:HZNP) was upgraded by The Goldman Sachs Group from a neutral rating to a buy rating in a report issued on Thursday, The Fly reports. HZNP has been the topic of several other reports. Jefferies Financial Group started coverage on Horizon Therapeutics Public in a report on Wednesday, October 13th. They set []

Campaign helps people know their risks and identify the signs and symptoms of TED to encourage early diagnosis and management - Horizon Therapeutics plc (Nasdaq: HZNP) today announced its support …

The CHMP gives a positive opinion on, and recommends approval to Horizon's (HZNP) Uplizna for treating adult patients with neuromyelitis optica spectrum disorder.

Beacon Pointe Advisors LLC acquired a new stake in shares of Horizon Therapeutics Public Limited (NASDAQ:HZNP) in the second quarter, HoldingsChannel reports. The fund acquired 3,146 shares of the biopharmaceutical companys stock, valued at approximately $295,000. A number of other hedge funds and other institutional investors have also modified their holdings of the business. Quadrant []

Horizon Therapeutics: Q3 Earnings Beat Not Enough For New Highs

Horizon's (HZNP) earnings and revenues beat estimates in the third quarter of 2021. The company lifts net sales guidance for 2021.

Horizon Therapeutics (HZNP) delivered earnings and revenue surprises of 13.64% and 5.78%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock

Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.

Horizon Therapeutics (HZNP) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.

Positive MIRROR Results An Important Step For Horizon Therapeutics' Gout Franchise